Computational modeling of hypercoagulability in COVID-19
- PMID: 36154346
- DOI: 10.1080/10255842.2022.2124858
Computational modeling of hypercoagulability in COVID-19
Abstract
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 100 million people worldwide and claimed millions of lives. While the leading cause of mortality in COVID-19 patients is the hypoxic respiratory failure from acute respiratory distress syndrome, there is accumulating evidence that shows excessive coagulation also increases the fatalities in COVID-19. Thus, there is a pressing demand to understand the association between COVID-19-induced hypercoagulability and the extent of formation of undesired blood clots. Mathematical modeling of coagulation has been used as an important tool to identify novel reaction mechanisms and to identify targets for new drugs. Here, we employ the coagulation factor data of COVID-19 patients reported from published studies as inputs for two mathematical models of coagulation to identify how the concentrations of coagulation factors change in these patients. Our simulation results show that while the levels of many of the abnormal coagulation factors measured in COVID-19 patients promote the generation of thrombin and fibrin, two key components of blood clots, the increased level of fibrinogen and then the reduced level of antithrombin are the factors most responsible for boosting the level of fibrin and thrombin, respectively. Altogether, our study demonstrates the potential of mathematical modeling to identify coagulation factors responsible for the increased clot formation in COVID-19 patients where clinical data is scarce.
Keywords: COVID-19; Coagulation; Mathematical Modeling; Precision Medicine.
Similar articles
-
COVID-19 coagulopathy - what should we treat?Exp Physiol. 2022 Jul;107(7):749-758. doi: 10.1113/EP089404. Epub 2022 Jun 22. Exp Physiol. 2022. PMID: 35733235 Free PMC article. Review.
-
Computational Prediction of the Interaction of Ivermectin with Fibrinogen.Int J Mol Sci. 2023 Jul 14;24(14):11449. doi: 10.3390/ijms241411449. Int J Mol Sci. 2023. PMID: 37511206 Free PMC article.
-
COVID-19: Not a thrombotic disease but a thromboinflammatory disease.Ups J Med Sci. 2024 Jan 22;129. doi: 10.48101/ujms.v129.9863. eCollection 2024. Ups J Med Sci. 2024. PMID: 38327640 Free PMC article. Review.
-
Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.Thromb Res. 2021 May;201:84-89. doi: 10.1016/j.thromres.2021.02.026. Epub 2021 Feb 24. Thromb Res. 2021. PMID: 33662799 Free PMC article.
-
Evaluation of COVID-19 coagulopathy; laboratory characterization using thrombin generation and nonconventional haemostasis assays.Int J Lab Hematol. 2021 Feb;43(1):123-130. doi: 10.1111/ijlh.13329. Epub 2020 Sep 5. Int J Lab Hematol. 2021. PMID: 32892505
Cited by
-
The association between mortality due to COVID-19 and coagulative parameters: a systematic review and meta-analysis study.BMC Infect Dis. 2024 Dec 2;24(1):1373. doi: 10.1186/s12879-024-10229-y. BMC Infect Dis. 2024. PMID: 39623325 Free PMC article.
-
Improved time-varying reproduction numbers using the generation interval for COVID-19.Front Public Health. 2023 Jun 30;11:1185854. doi: 10.3389/fpubh.2023.1185854. eCollection 2023. Front Public Health. 2023. PMID: 37457248 Free PMC article.
-
Coagulo-Net: Enhancing the mathematical modeling of blood coagulation using physics-informed neural networks.Neural Netw. 2024 Dec;180:106732. doi: 10.1016/j.neunet.2024.106732. Epub 2024 Sep 19. Neural Netw. 2024. PMID: 39305783
-
A mathematical model to assess the effects of COVID-19 on the cardiocirculatory system.Sci Rep. 2024 Apr 9;14(1):8304. doi: 10.1038/s41598-024-58849-3. Sci Rep. 2024. PMID: 38594376 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous